REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$930.67
−4.39%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$989.90
From 52W high−4.39%
Volume1.38M
Market cap$96.28B
P/E (TTM)19.8x
P/S (TTM)5.7x
Div yield0.40%
Key dataNov 4, 2026
Open
$989.90
From 52W high
−4.39%
Volume
1.38M
Market cap
$96.28B
ValuationView details →
P/E (Fwd)
11.6x
EV/EBITDA
14.4x
P/E (TTM)
19.8x
RSI (14)
78.3
MomentumView details →
1D Return
−4.39%
YTD Return
+24.41%
SummaryUpdated Sep 1, 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company went public in 1991 and has evolved from a research-focused startup into one of the world's premier biotechnology companies. Regeneron discovers, develops, manufactures, and commercializes innovative medicines for serious diseases across multiple therapeutic areas including ophthalmology, immunology, oncology, and rare diseases. The company is known for its proprietary drug discovery platforms and has built a portfolio of blockbuster medicines that serve patients worldwide.
Similar companies
Latest newsMore news →
REGENERON PHARMACEUTICALS, INC. reported third-quarter 2026 adjusted earnings of $20.07 per share, up 70% year over year and above the $16.19 analyst consensus estimate.2d agoRegeneron's stock rose.5d agoRegeneron reported third-quarter earnings and revenue above estimates, supported by Dupixent profits, Eylea HD growth and Libtayo demand.5d ago